Nuvation Bio Files 8-K on Financials

Ticker: NUVB · Form: 8-K · Filed: Mar 6, 2025 · CIK: 1811063

Sentiment: neutral

Topics: financial-condition, results-of-operations, exhibits

Related Tickers: NUVB

TL;DR

Nuvation Bio dropped an 8-K detailing its financial condition and results. Check it out.

AI Summary

Nuvation Bio Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, formerly known as Panacea Acquisition Corp. until April 30, 2020, is incorporated in Delaware and headquartered in San Francisco, California.

Why It Matters

This 8-K filing provides an update on Nuvation Bio's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Nuvation Bio Inc.?

The primary purpose of this 8-K filing is to report on Nuvation Bio Inc.'s results of operations and financial condition, and to include financial statements and exhibits.

When was this 8-K report filed?

This 8-K report was filed on March 6, 2025.

What was Nuvation Bio Inc.'s former company name?

Nuvation Bio Inc.'s former company name was Panacea Acquisition Corp., with a date of name change on April 30, 2020.

In which state is Nuvation Bio Inc. incorporated?

Nuvation Bio Inc. is incorporated in Delaware.

What are the principal executive offices of Nuvation Bio Inc.?

The principal executive offices of Nuvation Bio Inc. are located at 1500 Broadway, Suite 1401, New York, NY 10036.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 6, 2025 regarding Nuvation Bio Inc. (NUVB).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing